Statins for the primary prevention of cardiovascular disease (Q24201513)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

meta-analysis

0 references

title

Statins for the primary prevention of cardiovascular disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

main subject

cardiovascular disease

1 reference

1 reference

0 references

Kirsten Ward

0 references

George Davey Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Shah Ebrahim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Fiona Taylor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mark D Huffman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ana Filipa Macedo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Margaret Burke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Theresa H M Moore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kirsten Ward

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

31 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

CD004816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The impact of health care advice given in primary care on cardiovascular risk. CELL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Another look at the results of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The Jupiter trial: key findings, controversies, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The JUPITER trial: results, controversies, and implications for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The JUPITER Trial: Responding to the Critics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

C-reactive protein lowering with rosuvastatin in the METEOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statin cost-effectiveness in the United States for people at different vascular risk levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind t

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Framingham score and microalbuminuria: combined future targets for primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesteroal concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial?Lipid Lowering Arm (ASCOL-LLA): a multicentre ran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Long-term safety and efficacy profile of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Simvastatin in the treatment of asthma: lack of steroid-sparing effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Placing COURAGE in context: review of the recent literature on managing stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Reduction of heat shock protein antibody levels by statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: implications from the Japan Lipid Intervention Trial (J-LIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of lovastatin on cognitive function and psychological well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Behavioral implications of lowering cholesterol levels: a double-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Dementia and statins. PROSPER study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

High-risk elderly patients PROSPER from cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Preventing the next event in the elderly: the PROSPER perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Taking simvastatin in the morning compared with in the evening: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Are lipid-lowering guidelines evidence-based?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The causes and effects of socio-demographic exclusions from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Lifetime risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins and cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Plasma cholesterol concentration and mortality. The Whitehall Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Cholesterol and coronary heart disease: screening and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for all by the age of 50 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Selected major risk factors and global and regional burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Reducing the growing burden of cardiovascular disease in the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Serum total cholesterol and risk of hospitalization, and death from respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for primary prevention: at what coronary risk is safety assured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Reduced cholesterol is associated with recent minor illness: the CARDIA Study. Coronary Artery Risk Development in Young Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Improving vascular health: are pills the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Variations and increase in use of statins across Europe: data from administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

A systematic review and economic evaluation of statins for the prevention of coronary events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effectiveness of statin therapy in adults with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004816.PUB5

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

21 January 2018

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

1 reference

12 December 2020

The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?

1 reference

12 December 2020

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions

1 reference

12 December 2020

A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group

1 reference

12 December 2020

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

1 reference

12 December 2020

Long-term follow-up of the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China

1 reference

12 December 2020

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

12 December 2020

Storm over statins--the controversy surrounding pharmacologic treatment of children

1 reference

12 December 2020

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R

1 reference

12 December 2020

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

12 December 2020

Pravastatin benefits elderly patients: results of PROSPER study

1 reference

12 December 2020

Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis

1 reference

12 December 2020

Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias

1 reference

12 December 2020

Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA

1 reference

12 December 2020

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

What role for statins? A review and economic model.

1 reference

12 December 2020

Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

1 reference

12 December 2020

The PROSPER Study (PROspective study of pravastatin in the elderly at risk)

1 reference

12 December 2020

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

12 December 2020

The JUPITER trial: How will it change clinical practice?

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Res

1 reference

12 December 2020

Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

Atorvastatin normalizes endothelial function in healthy smokers

1 reference

12 December 2020

Effect of lifestyle and/or statin treatment on soluble markers of atherosclerosis in hypertensives

1 reference

12 December 2020

Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study

1 reference

12 December 2020

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

1 reference

12 December 2020

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

12 December 2020

Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin

1 reference

12 December 2020

Effects of Lovastatin on the Immune System

1 reference

12 December 2020

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003; 326: 1407-408.

1 reference

12 December 2020

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients

1 reference

12 December 2020

Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study

1 reference

12 December 2020

The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl

1 reference

12 December 2020

Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia

1 reference

12 December 2020

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

1 reference

12 December 2020

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause

1 reference

12 December 2020

Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study

1 reference

12 December 2020

Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Cholesterol lowering with statins: how WOSCOPS confounded the skeptics

1 reference

12 December 2020

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials

1 reference

12 December 2020

Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins

1 reference

12 December 2020

Carotid intima–media thickness: a suitable alternative for cardiovascular risk as outcome?

1 reference

12 December 2020

Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group

1 reference

12 December 2020

The CARDS trial: diabetic patients dealt a winning hand

1 reference

12 December 2020

Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients

1 reference

12 December 2020

Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease

1 reference

12 December 2020

Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels

1 reference

12 December 2020

Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

1 reference

12 December 2020

West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials

1 reference

12 December 2020

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

12 December 2020

Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus

1 reference

12 December 2020

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study

1 reference

12 December 2020

Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial

1 reference

12 December 2020

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

12 December 2020

[Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study]

1 reference

12 December 2020

Statin therapy for hypertensive patients

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

10.1002/14651858.CD004816.PUB5

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

160774

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

160774

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

23440795

2 references

Consolidated OpenCitations Corpus – April 2017

160774

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23440795%20AND%20SRC:MED&resulttype=core&format=json